

## pEF1 $\alpha$ -IRES-AcGFP1

**Catalog No(s).**  
631971

**Amount**  
20  $\mu$ l pEF1 $\alpha$ -IRES-AcGFP1 Vector (500 ng/ $\mu$ l)

**Lot Number**  
Specified on product label.

### pEF1 $\alpha$ -IRES-AcGFP1 Vector Information




Figure 1. pEF1 $\alpha$ -IRES-AcGFP1 vector map.

```

                NheI
                AfeI
1341 TCGTGACGCT  AGCGCTACCG  GACTCAGATC  TCGAGCTCAA
    AGCACTGCGA  TCGCGATGGC  CTGAGTCTAG  AGCTCGAGTT

                                SmaI
                                XmaI
1381 GCTTCGAATT  CTGCAGTCGA  CGGTACCGCG  GGCCCGGGAT  CCGCCCCTCT
    CGAAGCTTAA  GACGTCAGCT  GCCATGGCGC  CCGGGCCCTA  GCGGGGGAGA
                EcoRI                Sall                BamHI
                AccI
    
```

Figure 2. pEF1 $\alpha$ -IRES-AcGFP1 multiple cloning site.

## Location of Features

- $P_{EF1\alpha}$  (human elongation factor 1 alpha promoter): 12–1346
- MCS (multiple cloning site): 1348–1422
- IRES2 (internal ribosome entry site): 1423–2007
- AcGFP1 (human-codon-optimized): 2011–2727
- SV40 early polyA signal: 2883–2933
- f1 origin of replication: 2980–3435 (complementary)
- SV40 origin of replication: 3776–3911
- $P_{SV40e}$  (SV40 early promoter and enhancer sequences): 3609–3877
- Kan<sup>r</sup>/Neo<sup>r</sup> (kanamycin/neomycin resistance gene): 3960–4754
- HSV TK polyA signals: 4990–5008
- pUC origin of replication: 5339–5982

### NOTICE TO PURCHASER:

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, in vitro diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without prior written approval of Clontech Laboratories, Inc.

Your use of this product is also subject to compliance with the licensing requirements listed below and described on the product's web page at <http://www.clontech.com>. It is your responsibility to review, understand and adhere to any restrictions imposed by these statements.